Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

RecruitingHealthy volunteers welcome

Who can join

Ages 40 to 69 · Men · Healthy volunteers welcome

Full eligibility criteria

Inclusion Criteria:

* They must have the ability to understand and the willingness to sign a written information consent document.
* Estimated life expectancy of greater than 10 years.
* No history of prostate cancer.
* Participants must be between 40-69 years of age. This is the age at which screening for prostate cancer is recommended. This is due to younger patients not being at risk for the disease and older patients not benefiting from diagnosis.
* No biopsy for prostate cancer within the past 5 years.
* No prostate MRI within the past 5 years.

Exclusion Criteria:

* Unwillingness to sign the informed consent form.
* Contraindication to biopsy such as uncorrectable bleeding or coagulation disorder.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit the safety of a biopsy and/or surgery.
* Unable to undergo an MRI.

About the study

The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer.

The main questions it aims to answer are:

* If genetic data related to prostate cancer used with MRI can identify higher-grade, potentially fatal prostate cancer * What age a MRI is useful clinically for prostate cancer screening * If deep learning methods used with MRI when the genetic risk of the man is known can more accurately predict significant cancers

Participants will:

* Get a prostate specific antigen (PSA) blood test * Get an mpMRI * Get the results of their genetic data to determine if they are considered high-, intermediate-, or low-risk for prostate cancer based on the trials genetic testing * Follow-up for this trial based on the participants risk and findings from the PSA test and mpMRI

What is being tested

Polygenic Risk Score (PRS) (other)

Sponsor: Adam S. Kibel, MD · Participants: 1,500 · Started: May 7, 2024

Contact the study team

Adam S Kibel, MD, MHCM · Phone: (617) 525-7697
Daniella Furtado · Phone: (617) 525-8782

Official record on ClinicalTrials.gov — NCT06398639

Locations in the U.S.

District of Columbia	Howard University Hospital, Washington D.C. (Not yet recruiting)
Maryland	National Cancer Institute, Bethesda (Not yet recruiting) Walter Reed National Military Medical Center, Bethesda (Not yet recruiting)
Massachusetts	Brigham and Women's Hospital, Boston Massachusetts General Hospital, Boston

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.